Polyrizon Raises $4M in Registered Direct Offering and Private Placement
PLRZ has more than doubled off its 52-week low of $2.88 on elevated volume (2.3× avg).
Summary
Polyrizon entered definitive agreements with a single institutional investor for a $4.0 million registered direct offering and concurrent private placement. The deal includes 333,333 units at $12.00 per unit, each consisting of one ordinary share (or pre-funded warrant) and one common warrant with a $12.00 exercise price. The offering is expected to close on September 4, 2026, and proceeds will fund general corporate purposes and working capital. Following completion, the company will have 2,806,233 ordinary shares outstanding assuming exercise of all pre-funded warrants. This financing follows a series of positive clinical milestones for NASARIX™, including IRB approval and biocompatibility results, and provides near-term capital for continued development.
At the time of this announcement, PLRZ was trading at $12.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.